New Delhi: Jubilant Pharmova on Tuesday said it has appointed Daniel J O'Connor as the CEO of its proprietary novel drugs business.
O'Connor brings more than 30 years of leadership experience in biotechnology and oncology, with a proven record of creating value around differentiated, IP-rich platforms, the company said in a statement.
Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation, culminating in its successful acquisition, it added.
"We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications," its chairman Shyam S Bhartia said.
Jubilant Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients.
O'Connor brings more than 30 years of leadership experience in biotechnology and oncology, with a proven record of creating value around differentiated, IP-rich platforms, the company said in a statement.
Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation, culminating in its successful acquisition, it added.
"We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications," its chairman Shyam S Bhartia said.
Jubilant Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients.
